Deutsche Bank Aktiengesellschaft Reaffirms Hold Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “hold” rating reissued by research analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday,London Stock Exchange reports. They currently have a GBX 1,900 target price on the stock. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential downside of 6.42% from the company’s previous close.

A number of other brokerages have also issued reports on GSK. UBS Group reissued a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Berenberg Bank reissued a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. Citigroup raised their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a report on Monday, February 9th. Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research note on Tuesday, April 14th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of GBX 2,055.71.

GSK Trading Up 0.7%

LON:GSK traded up GBX 14.39 during trading hours on Tuesday, reaching GBX 2,030.39. The company’s stock had a trading volume of 125,907,813 shares, compared to its average volume of 10,466,653. The firm has a market capitalization of £81.15 billion, a price-to-earnings ratio of 14.63, a PEG ratio of 1.24 and a beta of 0.35. The firm has a 50-day simple moving average of GBX 2,101.81 and a 200-day simple moving average of GBX 1,920.52. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Research analysts expect that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In related news, insider Anne Beal acquired 196 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was purchased at an average cost of GBX 5,179 per share, with a total value of £10,150.84. Also, insider Jonathan Symonds acquired 5,000 shares of the firm’s stock in a transaction dated Friday, March 20th. The shares were bought at an average cost of GBX 1,951 per share, with a total value of £97,550. Insiders acquired a total of 11,452 shares of company stock valued at $24,283,952 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.